Riskpilot← Back to searchSign inGet full accessEndovascular Development AB
ABBankruptOrg 5567830673Research and experimental development on natural sciences and engineering · NACE 7210Est. 20090 employees
Revenue 2022
SEK 0
EBITDA margin
—
+42% vs 2021
Equity ratio
12.9%
Financial strength
Net profit 2022
SEK -777K
+82% vs 2021
| Revenue | SEK 0 | — |
| EBITDA | SEK -93K | +42% |
| Net profit | SEK -777K | +82% |
| Total assets | SEK 1,5M | -28% |
| Equity | SEK 190K | -74% |
| Employees | 0 | — |
Legal name
Endovascular Development AB
Org number
5567830673
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
26 maj 2009
Share capital
SEK 189 600
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Aktiebolagets verksamhet ska vara att bedriva utveckling, tillverkning och kommersialisering av metoder och produkter relaterade till behandling av kärlsjukdomar, ägande och förvaltande av värdepapper, fastigheter båtar och fordon samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 7 | 0 | 229 | 31 | 0 |
| Staff expenses | — | — | — | — | — | — | — | −0 |
| EBITDA | −1 801 | −3 162 | −3 423 | −1 608 | −2 036 | −2 220 | −161 | −93 |
| Depreciation & amort. | −8 | −8 | −630 | −1 033 | −1 033 | −1 024 | −4 136 | −532 |
| EBIT | −1 809 | −3 170 | −4 053 | −2 641 | −3 069 | −3 244 | −4 297 | −625 |
| Net financials | −7 | −5 | −4 | −1 | −2 | −47 | −84 | −152 |
| Profit before tax | −1 815 | −3 175 | −4 056 | −2 642 | −3 071 | −3 292 | −4 381 | −777 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — |
| Net profit | −1 815 | −3 175 | −4 056 | −2 642 | −3 071 | −3 292 | −4 381 | −777 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 9 616 | 10 596 | 10 842 | 8 125 | 7 295 | 7 042 | 2 036 | 1 465 |
| Equity | 9 349 | 10 174 | 10 118 | 7 475 | 6 404 | 5 112 | 731 | 190 |
| Long-term debt | 152 | 152 | 152 | 150 | 250 | 1 200 | 1 283 | 1 275 |
| Short-term debt | 115 | 270 | 572 | 500 | 641 | 729 | 21 | 0 |
| Total debt | 267 | 422 | 724 | 650 | 891 | 1 929 | 1 304 | 1 275 |
EBITDA margin
-9296300.0%
This company
15.8%
Market median
-58837442% vs market
20152022
Equity ratio
12.9%
This company
38.2%
Market median
-66% vs market
20152022
Return on equity
-409.7%
This company
18.4%
Market median
-2327% vs market
20152022
Net profit margin
-77722300.0%
This company
8.1%
Market median
-959534668% vs market
20152022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152022
Debt / equity
6.72×
This company
0.62×
Market median
-984% vs market
20152022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SS Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
PG Audit | Audit | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2020 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Liungman Transaktioner AB | Company | 63.0% | 63.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Liungman Transaktioner AB
Endovascular Development AB Board members of Endovascular Development AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Stefan Sowa | Chief Executive Officer | 0 companies |
| Per Gustaf Hammar | Audit | 0 companies |
| Eeva-Kaisa Marjukka Kuitunen | Deputy Board Member | 0 companies |
| Ellinor Anna Linnéa Nicolaou | Deputy Board Member | 0 companies |
| Carl Björn Krister Liungman | Chairman | 0 companies |
| Linus Peter Liungman Bosaeus | Board of Directors | 0 companies |